WB-4101 is a compound which acts as an
antagonist at the
α1B-adrenergic receptor. It was one of the first selective antagonists developed for this receptor and was invented in 1969, but is still commonly used in research into adrenergic receptors, especially as a
lead compound
A lead compound (, i.e. a "leading" compound, not to be confused with various compounds of the metallic element lead) in drug discovery is a chemical compound that has pharmacology, pharmacological or biological activity likely to be therapeutical ...
from which to develop more selective drugs.
See also
*
Phendioxan
References
Alpha-1 blockers
{{pharm-stub